- Home
- NFGC vs HELP Comparison
NFGC vs HELP Comparison
Compare NFGC & HELP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NFGC | HELP |
|---|---|---|
| Founded | 2016 | N/A |
| Country | Canada | Canada |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 760.5M | 712.2M |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | NFGC | HELP |
|---|---|---|
| Price | $2.00 | $13.94 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $51.50 |
| AVG Volume (30 Days) | 1.4M | ★ 1.8M |
| Earning Date | 05-11-2026 | 07-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $3,542.00 | N/A |
| Revenue Next Year | $118.57 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.34 | $3.76 |
| 52 Week High | $3.59 | $13.24 |
Technical Indicators
Market Signals| Indicator | NFGC | HELP |
|---|---|---|
| Relative Strength Index (RSI) | 69.26 | 77.36 |
| Support Level | $1.87 | $4.41 |
| Resistance Level | $2.10 | N/A |
| Average True Range (ATR) | 0.08 | 0.74 |
| MACD | 0.03 | 0.12 |
| Stochastic Oscillator | 88.10 | 100.00 |
Price Performance
Historical ComparisonAbout NFGC New Found Gold Corp
New Found Gold Corp is a mineral exploration company engaged in the acquisition, exploration and evaluation of resource properties with a focus on gold properties located in the Provinces of Newfoundland and Labrador and Ontario, Canada. The Companies exploration is focused on discovering and delineating gold resources. The Company has one material property: the Queensway Project located in Newfoundland, Canada (the Queensway Project).
About HELP Cybin Inc. Common Stock
Helus Pharma Inc, the commercial operating name of Cybin Inc, is a clinical-stage pharmaceutical company focused on developing proprietary neuroactive compounds, referred to as NSAs, which are synthetic molecules designed to target serotonin pathways. The company's programs are aimed at treating mental health conditions such as depression and anxiety. Its pipeline includes HLP003, which is in clinical development for the adjunctive treatment of depressive disorder, and HLP004, which is in clinical development for generalized anxiety disorder. The company also conducts research on additional investigational compounds.